Jaffer A. Ajani
The University of Texas MD Anderson Cancer Center(US)The University of Texas Health Science Center at San Antonio(US)
Publications by Year
Research Areas
Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment, Colorectal Cancer Treatments and Studies, Gastrointestinal Tumor Research and Treatment, Esophageal and GI Pathology
Most-Cited Works
- → Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction(2001)3,498 cited
- → First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial(2021)2,783 cited
- → Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial(2014)2,435 cited
- → Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group(2006)1,929 cited
- → Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer(2021)1,676 cited